Jaguar Health to report Phase 3 OnTarget trial results on or before July 23

Jaguar Health announced that it will hold an investor webcast on or before July 23, 2024 to provide results for the company’s pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy. The webcast, which will provide updates on Jaguar’s advancing cancer supportive care portfolio, will include members of Jaguar’s scientific team, patient advocates, and leading oncology experts on two of the most common and intolerable side effects of cancer therapy: CTD and oral mucositis. “Patients are the heart of our mission at Jaguar,” said Lisa Conte, the company’s president and CEO. “The thorough and exhaustive OnTarget prophylactic protocol allowed for the inclusion of all treatment needs for participating patients with solid tumors and targeted therapy, including any supportive care. We look forward to receiving and providing the results with the anticipation we know all our stakeholders share. As with many pharmaceutical companies involved with an expansive global pivotal study, we use several third-party contractors. In order to address the complexity of OnTarget’s statistical programming needs – as the trial involves multiple solid tumor types, 23 targeted therapies, six countries, daily patient-reported outcomes covering anywhere from 90 to 180 days with multiple entries a day, and concomitant medications – we retained a clinically experienced biostatistics and programming expert to review and lead the statistical programming and the implementation of the statistical analysis plan submitted to the FDA. The third-party vendors who are conducting the analysis of patient data for the OnTarget trial have identified the key necessary steps required to share results with Jaguar on or before July 23, allowing us to set a date for the findings.”